Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled randomized multicenter study of CSL312 for prevention of hereditary angioedema attacks
MOH_2019-03-19_006035Phase 2Active, not recruiting
- Sponsor
- CSL Limited
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of garadacimab in hereditary angioedema (HAE) (6 arms), sponsored by CSL Limited. Primary endpoint: Not reported. Started Dec 2018; status: active, not recruiting.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on MOH_2019-03-19_006035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-19_006035.